摘要
目的 探讨老年留置导尿管患者铜绿假单胞菌泌尿系统感染采用头孢他啶联合阿米卡星治疗的效果。方法 选取2025年1月-2026年2月接收的58例留置导尿管铜绿假单胞菌泌尿系统感染老年患者，按治疗方案差异分为两组，27例接受头孢他啶治疗为单药组，31例接受头孢他啶联合阿米卡星治疗为联合组，对比两组血清炎性因子、尿液细菌学指标、总有效率及不良反应。结果 联合组治疗后尿细菌计数、尿液中白细胞计数较单药组低（P＜0.05）；联合组总有效率（96.77%）较单药组（77.78%）高（P＜0.05）；联合组不良反应（6.45%）与单药组（3.70%）无差异（P＞0.05）。结论 在留置导尿管患者铜绿假单胞菌泌尿系统感染老年患者中，实施头孢他啶联合阿米卡星可促进其尿液细菌学指标有效改善，达到良好疗效，且安全性理想。
关键词： 头孢他啶；阿米卡星治疗；导尿管；铜绿假单胞菌；泌尿系统感染
Abstract
Objective To investigate the efficacy of ceftazidime combined with amikacin in treating urinary tract infections caused by Pseudomonas aeruginosa in elderly patients with indwelling urinary catheters. Methods A total of 58 elderly patients with Pseudomonas aeruginosa-induced urinary tract infections and indwelling urinary catheters admitted between January 2025 and February 2026 were selected and divided into two groups based on treatment regimens: 27 patients received ceftazidime monotherapy (monotherapy group), and 31 patients received ceftazidime combined with amikacin (combined group). Serum inflammatory factors, urinary bacteriological indicators, total effective rate, and adverse reactions were compared between the two groups. Results Post-treatment, the urinary bacterial count and white blood cell count in the combined group were lower than those in the monotherapy group (P < 0.05). The total effective rate in the combined group (96.77%) was higher than that in the monotherapy group (77.78%) (P < 0.05). There was no significant difference in adverse reactions between the combined group (6.45%) and the monotherapy group (3.70%) (P > 0.05). Conclusion In elderly patients with indwelling urinary catheters and Pseudomonas aeruginosa-induced urinary tract infections, the combination of ceftazidime and amikacin effectively improves urinary bacteriological indicators, achieves favorable therapeutic outcomes, and demonstrates ideal safety.
Key words： Ceftazidime; Amikacin therapy; Urinary catheter; Pseudomonas aeruginosa; Urinary tract infection
参考文献 References
[1] 兰婷钰,贺洪武,明星,等.综合干预措施降低导尿管相关尿路感染的效果评价[J].中国感染控制杂志,2025,24(2): 201-206.
[2] 李华燕,晏媛,曾洁,等.肺部铜绿假单胞菌感染的抗菌药物治疗研究现状[J].医学综述,2023,29(17):3465-3469.
[3] 李露,刘爽,崔开宇,等.痰热清注射液与头孢他啶联用对铜绿假单胞菌的体外耐药敏化作用研究[J].北京中医药, 2023,42(8):824-830.
[4] 沈怡萱,岳建宏,李明珠,等.氨溴索联合阿米卡星治疗COPD合并呼吸机相关性肺炎患者的疗效[J].中国药物应用与监测,2025,22(5):824-828.
[5] 范燕红,陆佳韵,戴华,等.《APSIC预防导尿管相关性尿路感染指南》解读[J].中华现代护理杂志,2024,30(19): 2521 -2525.
[6] 林秀慧,许政衡,林秀华,等.老年导尿管相关尿路感染生物被膜菌分布特征及生物被膜形成相关基因[J].中华医院感染学杂志,2023,33(5):718-722.
[7] 韩萍,赵建清,张伟,等.碳青霉烯类耐药铜绿假单胞菌感染及预后的风险因素研究进展[J].中国医药导报,2025, 22(4):56-60.
[8] 张海燕,吴莉莉,尹远远,等.视频脑电图联合C反应蛋白和降钙素原对伴惊厥发作中枢神经系统感染性疾病的诊断价值研究[J].中国医学装备,2025,22(4):43-47.
[9] 郑笑然,张秀伟,高晨曦,等.壳聚糖装载GLP-1联合头孢他啶雾化治疗铜绿假单胞菌肺部感染的临床研究[J].黑龙江医药,2025,38(5):1013-1017.
[10] 张天棋,陈碧,张灿堂.头孢他啶/阿维巴坦联合阿米卡星治疗CRE感染重症肺炎的疗效与安全性分析[J].中国药房,2025,36(21):2705-2710.